# Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males

> **NCT06509139** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **National Cheng-Kung University Hospital** · enrollment: 661 (estimated)

## Conditions studied

- Helicobacter Pylori Infection
- Sex
- Bismuth Quadruple Therapy

## Interventions

- **DRUG:** Drug: Bismuth Subcitrate 120 MG Oral Tablet
- **DRUG:** Esomeprazole 40mg
- **DRUG:** Metronidazole 250 MG
- **DRUG:** Tetracycline Pill

## Key facts

- **NCT ID:** NCT06509139
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-07-09
- **Primary completion:** 2032-07-31
- **Final completion:** 2032-07-31
- **Target enrollment:** 661 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06509139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06509139, "Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06509139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*